旗下部分产品近一年收益不佳 【深圳商报讯】（记者 詹钰叶）在市场近期回暖的背景下，林园旗下部分产品业绩不佳，被部分持有 人吐槽"错过牛市"。不过，也有多位财经博主力挺。林园表示依然看好A股，建议关注颜值经济与银发 经济。 去年"9·24"以来A股回暖，今年人工智能、创新药等板块表现十分活跃，结构性行情突出。据同花顺 （300033）数据，今年前三季度，上证指数累计上涨近16%，深证成指涨近30%，创业板指涨逾50%， 沪深300涨近18%，科创综指涨逾53%。而林园旗下部分产品表现不佳，近20只产品跑输沪深300同期表 现，还有产品出现亏损，引发持有人不满。 有博主晒出的持仓截图显示，其持有林园投资173号私募产品，金额为99.48万元，截至9月26日的最新 净值为0.7598，浮动盈亏为-60.52万元，持有期间亏损37.82%。支持林园的博主认为投资需要看长期收 益，"短期内一两年落后很正常"；"他以前买茅台也是一样的经历，只有不懂价值投资的人才会喷"。也 有博主表示，在市场风格转换的情况下，林园依然坚持此前赛道，"押错方向出现这个成绩不奇怪"。 私募排排网数据显示，林园投资旗下有业绩显示的19只产品，其 ...

Core Viewpoint - Lin Yuan remains optimistic about the A-share market despite some underperformance of his investment products, suggesting a focus on "beauty economy" and "silver economy" as future investment themes [1][2][3] Group 1: Market Performance - The A-share market has shown a significant recovery, with the Shanghai Composite Index up nearly 16%, the Shenzhen Component Index up nearly 30%, and the ChiNext Index up over 50% in the first three quarters of the year [1] - Lin Yuan's products have underperformed, with nearly 20 products lagging behind the CSI 300 Index, and some even reporting losses, leading to dissatisfaction among investors [1][2] Group 2: Investment Strategy - Lin Yuan's investment strategy focuses on sectors with strong earnings potential and monopolistic characteristics, particularly in consumer and pharmaceutical industries [2] - He emphasizes the importance of long-term returns, arguing that short-term underperformance is not unusual in value investing [1][2] Group 3: Future Outlook - Lin Yuan identifies two key areas for future investment: the "beauty economy," which he believes will be a critical factor in society, and the demand for health and longevity products as the population ages [2] - He asserts that the current A-share market sentiment is rational, with most companies' stock prices and valuations still at historical lows compared to the past two decades [3]

Core Viewpoint - The performance of Lin Yuan's private equity fund products has sparked significant discussion, particularly regarding the substantial losses experienced by some funds, highlighting the challenges faced in the current market environment [1][3][5]. Fund Performance Summary - Lin Yuan Investment No. 173, established in October 2020, has a net value of 0.7598 as of September 26, 2023, reflecting a cumulative loss of 24% since inception and a loss of 3.7% year-to-date [3][4]. - The fund's holder reported a floating loss of 605,200 yuan, equating to a 37.82% loss during the holding period [1]. - Other funds under Lin Yuan's management have also reported negative returns this year, with 19 products underperforming compared to the CSI 300 index, and 6 of these funds showing losses [5]. Market Reactions and Commentary - Financial commentators have expressed mixed sentiments regarding Lin Yuan's investment strategy, with some defending his approach to value investing despite current losses, while others criticize the performance of his funds [1][5]. - Lin Yuan has acknowledged the challenges in the market, particularly in traditional sectors like liquor and pharmaceuticals, and noted that his recent investments in technology stocks were minimal and largely passive [5].